52 citations
,
October 2012 in “Journal of Dermatological Science”
The document concludes that mouse models are crucial for studying hair biology and that all mutant mice may have hair growth abnormalities that require detailed analysis to identify.
The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactinreceptorinhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.
ABS-201, a prolactinreceptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactinreceptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
The conclusion of the conversation is that the user should consider using treatments such as finasteride, minoxidil, and RU58841 to potentially reverse their hair loss. Other suggestions include using hair loss concealers and maintaining a healthy diet.